

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

**VOLUNTARY ANNOUNCEMENT
INCLUSION IN THE LIST OF ELIGIBLE SECURITIES
OF HONG KONG STOCK CONNECT**

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest development of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that, according to the Notice of Adjustment of the Eligible Securities in Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect (《關於滬港通下港股通標的調整的通知》) and the Announcement on Adjustment of the List of the Eligible Securities in Hong Kong Stock Connect under the Shenzhen-Hong Kong Stock Connect (《關於深港通下的港股通標的證券名單調整的公告》) issued by the Shanghai Stock Exchange and the Shenzhen Stock Exchange respectively, the Company was included in the list of eligible securities of Hong Kong Stock Connect under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, with effect from 7 September 2026.

The Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect are channels for stock trading and investment between investors in the capital markets of Hong Kong and Chinese Mainland. The inclusion of the Company in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect will help to expand the Company’s shareholder base and enhance the liquidity of the Company’s shares, thereby further enhancing the Company’s investment value in the capital market.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 7 September 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.